You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re

    SBC: Apogee Biotechnology Corporation            Topic: 102

    DESCRIPTION provided by applicant Diffuse large B cell lymphoma DLBCL represents one of the most common variants of Non Hodgkinandapos s lymphoma NHL and oncogenic herpesviruses EBV and KSHV are the etiologic agents for the majority of these tumors in patients over or those infected with the human immunodeficiency virus HIV Despite modest improvements in outcomes for patients rece ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Wireless Device to Monitor and Track Fluid Consumption in At-Risk Older Adults

    SBC: Smart Activity of Daily Living, LLC            Topic: NINR

    DESCRIPTION (provided by applicant): The long term goal of the proposed project by Smart Activities of Daily Living, LLC (Smart ADLs) is to develop a device (the Smart Cup) that will improve the health of older adults by managing nutrition using smart health technology. Malnutrition (under nutrition) is a common geriatric syndrome found in older adults across the care continuum. Older adults accou ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Corrosion Protection of High-Value Test&Evaluation Assets

    SBC: eSpin Technologies, Inc.            Topic: MDA13T010

    This STTR Phase I proposal proposes to design and develop reactive filter media using nanofiber technology to capture corrosion inducing particulate matter present in coastal region air. The fibrous filter media will be functionalized using ion exchange chemistry which is known to react with salt ions. The media will be characterized for its filtration performance, resistance to airflow, and dus ...

    STTR Phase I 2014 Department of DefenseMissile Defense Agency
  4. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: LIPELLA PHARMACEUTICALS INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. (Pittsburgh, PA) is a clinical-stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions. Lipella is submitting a research proposal to the Small Business Technology Transfer program titled Developing Intravesical Liposomes for Interstitial Cystitis . The project proposes to evaluate the sa ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Intravesical Liposomes for Interstitial Cystitis

    SBC: LIPELLA PHARMACEUTICALS INC.            Topic: NIDDK

    DESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions Lipella is submitting a research proposal to the Small Business Technology Transfer program titled andquot Developing Intravesical Liposomes for Interstitial Cystitisandquot The project proposes to e ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Compounds for the Prevention and Treatment of Rhabdomyolysis

    SBC: Virtual Drug Development Inc.            Topic: NIDDK

    ? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid, Accurate, and Low-Cost Stool Clostridium difficile Genetic Test

    SBC: Lenima Field Diagnostics LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Clostridium difficile (CD) is a bacterium causing diarrhea and other intestinal problems linked to 14,000 annual deaths in the US. CDI is an antibiotic-associated infection as well as a health-care-associated infection.Current CDI diagnosis relies on CD toxins enzyme immunoassay (EIA) together with antigen (GDH) EIA. Although stool toxin EIA is specific and rel ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    We have discovered the first-ever inhibitors of PF4, a platelet protein central to the pathophysiology of heparin induced thrombocytopenia (HIT). Heparin is a naturally-occurring anticoagulant that prevents the formation of clots and extension of existingclots within the vasculature, and major medical applications of heparin include dialysis, cardiac catheterization, and cardiopulmonary bypass sur ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIGMS

    DESCRIPTION: While HIV/AIDS can be managed with antiretroviral drugs that block viral replication, these agents do not clear the virus and require life-long drug administration with associated risks of cumulative toxicity and drug resistance. Recently, wediscovered a completely new class of compounds that interfere with the HIV-1 virulence factor, Nef. This viral protein is critical to HIV-1 repli ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): There is an urgent, unmet need for novel therapeutic approaches that are efficacious against lung cancer. Ranking first among cancer deaths in the U.S., this disease has 5-year relative survival rates of lt20%. Most lung cancers are non-small cell (NSCLC, 85% of cases). Curative surgery is not an option for the 80% of NSCLC patients who present with advanced s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government